Biotech Values

[DewDiligence]

The safety hurdles are much lower than in virtually any other space, and reimbursement is also pretty clear.

There are still only so many reimbursement dollars in the aggregate available for cancer drugs, no matter how impressive their efficacy and tolerability may be by historical standards.

In short, there simply aren’t going to be that many Ponatinibs.